SCHEMBL897124

SCHEMBL897124

CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](OP(=O)(O)OP(=O)(O)O)[C@H]1OP(=O)(O)OP(=O)(O)O

nearest known ligand 0.62

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
LGALS8 O00214 6/20 0.46
FGF1 P05230 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30360450 0.85 P2RY14 (0.39) LGALS8
SCHEMBL22393 0.81 SMPD1 (0.40)
Pyrophosphoric Acid SCHEMBL7582145 0.80 SMPD1 (0.39)
SCHEMBL30007287 0.80 SMPD1 (0.39)
SCHEMBL118472 0.80 LGALS8 (0.47) LGALS8FGF1
SCHEMBL7856353 0.80 LGALS8 (0.50) LGALS8FGF1
SCHEMBL29656742 0.79 P2RY14 (0.47)
SCHEMBL3360274 0.79 P2RY14 (0.47)
SCHEMBL7568898 0.78 P2RY14 (0.49)
SCHEMBL7568791 0.78 P2RY14 (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140155334-A1 POLYPHOSPHATE AND PYROPHOSPHATE DERIVATIVE OF SACCHARIDES UNIVERSITÉ DE STRASBOURG (FR) 2014-06-05 US claimed
US-20140088036-A1 POLYPHOSPHATE AND PYROPHOSPHATE DERIVATIVE OF SACCHARIDES UNIVERSITE DE STRASBOURG (FR) 2014-03-27 US claimed
US-20210361680-A1 INOSITOL-BASED IMMUNOTHERAPIES NORMOXYS INC (US) 2021-11-25 US disclosed
EP-3787634-A1 INOSITOL-BASED IMMUNOTHERAPIES NormOxys, Inc. (US) 2021-03-10 EP disclosed
US-20160067267-A1 MYO-INOSITOL TRISPYROPHOSPHATE AS AN ANTI-OBESITY AGENT NORMOXYS, INC. (US) 2016-03-10 US disclosed
WO-2015138916-A1 MYO-INOSITOL TRISPYROPHOSHATE AS AN ANTI-DIABETIC AGENT NICOLAU YVES CLAUDE (US) 2015-09-17 WO disclosed
US-20140155334-A1 POLYPHOSPHATE AND PYROPHOSPHATE DERIVATIVE OF SACCHARIDES UNIVERSITÉ DE STRASBOURG (FR) 2014-06-05 US disclosed
US-20140088036-A1 POLYPHOSPHATE AND PYROPHOSPHATE DERIVATIVE OF SACCHARIDES UNIVERSITE DE STRASBOURG (FR) 2014-03-27 US disclosed
EP-2621273-A2 POLYPHOSPHATE AND PYROPHOSPHATE DERIVATIVE OF SACCHARIDES Normoxys, Inc. (US) 2013-08-07 EP disclosed
WO-2012045009-A2 POLYPHOSPHATE AND PYROPHOSPHATE DERIVATIVE OF SACCHARIDES NORMOXYS, INC. (US) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155334-A1 POLYPHOSPHATE AND PYROPHOSPHATE DERIVATIVE OF SACCHARIDES PPIP5K2, INPP5A, INPP5B LGALS8 2498/4885FGF1 2368/4885
US-20140088036-A1 POLYPHOSPHATE AND PYROPHOSPHATE DERIVATIVE OF SACCHARIDES PPIP5K2, INPP5A, INPP5B LGALS8 2498/4885FGF1 2368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.